Special Issue

New Directions in Stereotactic Radiotherapy

Message from the Guest Editor

Dear colleagues, Stereotactic Body Radiation Therapy (SBRT) implies the delivery of large doses of radiation to very small volumes, in a very short period of time, using sophisticated technology to plan and to deliver the treatment. SBRT has become a valuable adjunct to standard surgery and chemotherapy in some situations. and a viable alternative to surgery in other situations. In a very short time, it has grown from being a highly specialized intervention practiced by only a few centres, becoming a modern standard-of-care at most academic centres. In doing so, SBRT has offered improved outcomes to our patients, and exciting new opportunities to our clinicians and researchers. The burden of cancer continues to grow as and our population continues to age. SBRT is a powerful weapon in our battle against cancers of all types.

Guest Editor

Dr. Brian Yaremko

Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON N6A 3K7, Canada

Deadline for manuscript submissions

closed (10 June 2022)



Current Oncology

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/75543

Current Oncology Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 currentoncology@mdpi.com

mdpi.com/journal/curroncol





Current Oncology

an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 4.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

- College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada
- 2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)

